Monoclonal antibody
Injectable
By intravenous (IV) injection
Ocrevus is indicated for the treatment of relapsing and primary progressive MS. It is not a cure for MS, but it may help slow nerve damage while delaying physical disability and the frequency of relapses. It is indicated for use by adults only.
Ocrevus is a medication that works by targeting a specific protein called CD20 that sits on the outside of certain immune cells known as B-lymphocytes. These cells play a role in the development of MS symptoms. When Ocrevus attaches to the CD20 protein, it signals the body's defense system to get rid of these B-cells, which may help slow down the worsening of MS and lead to fewer episodes where symptoms get worse, which are called relapses.
This medication is FDA-approved to manage certain forms of MS, including primary progressive MS (PPMS) and relapsing forms. It is typically administered by infusion over two to three hours or longer every six months, always under the supervision of a healthcare professional to manage any immediate reactions.
Patients taking Ocrevus might have side effects such as headaches, fatigue, or skin reactions. To help lower the risk of side effects, healthcare providers often give medications before the infusion and watch patients closely afterward. Also, because Ocrevus can weaken the immune system, it may increase the chances of getting infections or cancer.
Before starting Ocrevus therapy, patients should understand that it's not a cure for MS but may manage symptoms and slow disease progression. Tell a healthcare provider about any medical conditions, history of infections, and other medications being taken before taking the first dose of Ocrevus.
Fact-check the list of forms below, removing any forms that do not apply to Ocrevus.
Add information about strengths below each form.
Injection
300 mg/10 mL
The standard starting dose is 600 mg divided into two separate doses of 300 mg each. These initial 300 mg doses are administered via IV infusion, each over a period of approximately 2.5 hours. The two starting doses are given two weeks apart.
After the initial doses, a 600 mg dose is administered every six months as a single infusion over 2 hours or longer. Some patients may require a longer infusion time, especially if the infusion rate needs adjusting due to a reaction.
Ocrevus
10ml of 300mg/10ml vial
Your healthcare provider will prescribe your dose and schedule. This medicine is given through a needle placed in a vein and delivered as an infusion.
Patients may receive other medications before the start of an Ocrevus infusion to reduce the risk of reactions. These medications often include corticosteroids, antihistamines, and possibly a fever reducer.
After receiving Ocrevus, patients will be observed for signs of side effects. Healthcare providers usually monitor patients for a period, often at least an hour, after the infusion is complete.
Patients don't need to worry about storing the medication, as it's stored and prepared by the medical facility providing the treatment.
If you miss an Ocrevus infusion, get it as soon as you can instead of waiting for the next scheduled dose.
After the missed dose is given, schedule your following dose for six months later, making sure there's at least a five-month gap between doses.
This medicine is not right for everyone. You should not receive it if you have had a life-threatening reaction to ocrelizumab or if you have an active hepatitis B infection.
Patients may experience infusion reactions. Symptoms can include itching, rash, hives, or swelling of the lips, tongue, or throat.
There might be a reduction in immunoglobulin levels with long-term use, which could affect the immune system's ability to fight infections. As a result, Ocrevus can increase the risk of infections, including upper respiratory tract and herpes-related infections.
Reactivation of hepatitis B virus can occur. Patients should get screened for hepatitis B before starting treatment.
A rare brain infection called progressive multifocal leukoencephalopathy (PML) has been reported with Ocrevus; patients should be observant of any new or worsening neurological symptoms.
There may be an increased risk of cancer, particularly breast cancer, so regular screening is advised.
Patients should complete any required vaccinations at least four weeks prior to starting Ocrevus for live or live-attenuated vaccines and, when possible, two weeks prior to starting Ocrevus for non-live vaccines.
Women need to discuss the potential risks and benefits with their doctor if they are pregnant, planning to become pregnant, or breastfeeding. Use an effective form of birth control during treatment with this medicine and for six months after the last dose.
If you're taking steroids or any drugs that affect your immune system, like daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, let your healthcare provider know. These medicines could make Ocrevus less effective or increase the chances of weakening your immune system. It's especially important to consider the risk of an interaction if you're switching from one of these drugs to Ocrevus, due to their lasting effects.
This medicine may interfere with vaccines. Ask your doctor before you get a flu shot or any other vaccine. You may receive live or live-attenuated vaccines at least four weeks or non-live vaccines at least two weeks before starting this medicine.
Serious side effects
Weakened immune system and an increased risk of infections, such as viral, bacterial, and fungal infections. This medication may reactivate a hepatitis B infection in people who have had the infection before.
Infusion reactions could range from mild to serious and may include symptoms such as fever, hives, skin rash, rapid heartbeat, fatigue, headache, nausea, or difficulty breathing.
Increased risk of progressive multifocal leukoencephalopathy, a rare brain infection that can lead to severe disability or death.
Less serious side effects
Feeling depressed or sad
Pain, itching, burning, swelling, or a lump under your skin where the needle is placed
Back, arm, or leg pain
Ocrevus highlights of prescribing information, U.S. Food and Drug Administration (2024)
Ocrevus, Medline Plus (2022)
Gerardo Sison, Pharm.D., graduated from the University of Florida. He has worked in both community and hospital settings, providing drug information and medication therapy management services. As a medical writer, he hopes to educate and empower patients to better manage their health and navigate their treatment plans.
...SingleCare es un servicio de descuentos para medicamentos recetados que ofrece cupones gratuitos para miles de medicamentos. Puedes usarlo aun si tienes seguro, Medicare, Medicaid o no, pero no se puede combinar con el seguro.
SingleCare ofrece transparencia al mostrar los precios de medicamentos para que puedas comparar descuentos en farmacias cerca de ti. Visita singlecare.com para encontrar descuentos en medicamentos, información útil sobre tu receta médica y recursos que te ayudan a tomar decisiones informadas sobre tu salud.
Los ahorros en recetas varían según la receta médica y la farmacia, y pueden alcanzar hasta un 80% de descuento sobre el precio en efectivo. Este es un plan de descuento de recetas médicas. NO es un seguro ni un plan de medicamentos de Medicare. El rango de descuentos para las recetas médicas que se brindan bajo este plan, dependerá de la receta y la farmacia donde se adquiera la receta y puede otorgarse hasta un 80% de descuento sobre el precio en efectivo. Usted es el único responsable de pagar sus recetas en la farmacia autorizada al momento que reciba el servicio, sin embargo, tendrá el derecho a un descuento por parte de la farmacia de acuerdo con el Programa de Tarifas de Descuento que negoció previamente. Towers Administrators LLC (que opera como “SingleCare Administrators”) es la organización autorizada del plan de descuento de recetas médicas ubicada en 4510 Cox Road, Suite 11, Glen Allen, VA 23060. SingleCare Services LLC (“SingleCare”) es la comercializadora del plan de descuento de prescripciones médicas que incluye su sitio web www.singlecare.com. Como información adicional se incluye una lista actualizada de farmacias participantes, así como también asistencia para cualquier problema relacionado con este plan de descuento de prescripciones médicas, comunícate de forma gratuita con el Servicio de Atención al Cliente al 844-234-3057, las 24 horas, los 7 días de la semana (excepto los días festivos). Al utilizar la aplicación o la tarjeta de descuento para recetas médicas de SingleCare acepta todos los Términos y Condiciones, para más información visita: https://www.singlecare.com/es/terminos-y-condiciones. Los nombres, logotipos, marcas y otras marcas comerciales de las farmacias son propiedad exclusiva de sus respectivos dueños.
Los artículos del blog no constituyen asesoramiento médico. Su propósito es brindar información general y no sustituyen el asesoramiento, diagnóstico ni tratamiento médico profesional. Si tiene alguna pregunta sobre una afección médica, consulte siempre a su médico u otro profesional de la salud cualificado. Si cree tener una emergencia médica, llame inmediatamente a su médico o al 911.
© 2025 SingleCare Administrators. Todos los derechos reservados
© 2025 SingleCare Administrators. Todos los derechos reservados